Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor
antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Empagliflozin Interleukin 1 Receptor Antagonist Protein